MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida. Show more

1200 Brickell Avenue, Miami, FL, 33131, United States

Drug Manufacturers - General
Healthcare

Market Cap

39.92M

52 Wk Range

$0.90 - $2.45

Previous Close

$0.95

Open

$0.96

Volume

42,935

Day Range

$0.95 - $0.99

Enterprise Value

30.51M

Cash

9.407M

Avg Qtr Burn

-1.201M

Insider Ownership

16.71%

Institutional Own.

5.03%

Qtr Updated

03/31/26